| Therachoice Inc. | |
|
111 2nd Ave Ne, Suite 900, St Petersburg, FL 33701-3434 | |
| (813) 690-1327 | |
| (727) 823-3702 |
| Full Name | Therachoice Inc. |
|---|---|
| Type | Facility |
| Speciality | Speech-language Pathologist |
| Location | 111 2nd Ave Ne, St Petersburg, Florida |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073851879 | NPI | - | NPPES |
| 007967300 | Medicaid | FL |
| Provider Name | Kristin S Cummings |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1073808523 PECOS PAC ID: 1153699954 Enrollment ID: I20170620002749 |
News Archive
Access Pharmaceuticals, Inc., announced today that it has entered into a pre-licensing feasibility agreement with a leading biotechnology company to develop an oral formulation of its currently-marketed, proprietary injectable drugs. Access will utilize its proprietary Cobalamin Oral Drug Delivery Technology to develop oral formulations of the drug for pre-clinical testing.
Dr. Megan Rockafellow-Baldoni, Rutgers School of Public Health alum and Center for Public Health Workforce Development program coordinator, has found a reduction in the risk of cancer due to arsenic exposure in Hopewell Township (Mercer County), New Jersey with use of arsenic treatment systems. Arsenic exists in varying levels in all parts of New Jersey; chronic exposure can increase rates of bladder, lung, liver, kidney, and skin cancers.
Heart function significantly improved in children and young adults with single ventricle congenital heart disease who have had the Fontan operation following treatment with sildenafil, a drug used to treat erectile dysfunction and pulmonary hypertension, say researchers from The Children's Hospital of Philadelphia.
The respective microRNA seed region influences the production of sensory hair cells in the inner ear, both in the mouse and in humans.
IDEXX Laboratories, Inc., today reported that revenues for the fourth quarter of 2011 increased 8% to $307.2 million, from $283.8 million for the fourth quarter of 2010. Organic revenue growth, as defined below, was 7%. Earnings per diluted share ("EPS") for the quarter ended December 31, 2011 increased 8% to $0.67, compared to $0.62 for the same period in the prior year.
› Verified 3 days ago
| Provider Name | Karlee Fisher |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1063862332 PECOS PAC ID: 8325312325 Enrollment ID: I20170914000836 |
News Archive
Access Pharmaceuticals, Inc., announced today that it has entered into a pre-licensing feasibility agreement with a leading biotechnology company to develop an oral formulation of its currently-marketed, proprietary injectable drugs. Access will utilize its proprietary Cobalamin Oral Drug Delivery Technology to develop oral formulations of the drug for pre-clinical testing.
Dr. Megan Rockafellow-Baldoni, Rutgers School of Public Health alum and Center for Public Health Workforce Development program coordinator, has found a reduction in the risk of cancer due to arsenic exposure in Hopewell Township (Mercer County), New Jersey with use of arsenic treatment systems. Arsenic exists in varying levels in all parts of New Jersey; chronic exposure can increase rates of bladder, lung, liver, kidney, and skin cancers.
Heart function significantly improved in children and young adults with single ventricle congenital heart disease who have had the Fontan operation following treatment with sildenafil, a drug used to treat erectile dysfunction and pulmonary hypertension, say researchers from The Children's Hospital of Philadelphia.
The respective microRNA seed region influences the production of sensory hair cells in the inner ear, both in the mouse and in humans.
IDEXX Laboratories, Inc., today reported that revenues for the fourth quarter of 2011 increased 8% to $307.2 million, from $283.8 million for the fourth quarter of 2010. Organic revenue growth, as defined below, was 7%. Earnings per diluted share ("EPS") for the quarter ended December 31, 2011 increased 8% to $0.67, compared to $0.62 for the same period in the prior year.
› Verified 3 days ago
| Provider Name | Andrea Marie Conard |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1164883187 PECOS PAC ID: 6608128657 Enrollment ID: I20181003000436 |
News Archive
Access Pharmaceuticals, Inc., announced today that it has entered into a pre-licensing feasibility agreement with a leading biotechnology company to develop an oral formulation of its currently-marketed, proprietary injectable drugs. Access will utilize its proprietary Cobalamin Oral Drug Delivery Technology to develop oral formulations of the drug for pre-clinical testing.
Dr. Megan Rockafellow-Baldoni, Rutgers School of Public Health alum and Center for Public Health Workforce Development program coordinator, has found a reduction in the risk of cancer due to arsenic exposure in Hopewell Township (Mercer County), New Jersey with use of arsenic treatment systems. Arsenic exists in varying levels in all parts of New Jersey; chronic exposure can increase rates of bladder, lung, liver, kidney, and skin cancers.
Heart function significantly improved in children and young adults with single ventricle congenital heart disease who have had the Fontan operation following treatment with sildenafil, a drug used to treat erectile dysfunction and pulmonary hypertension, say researchers from The Children's Hospital of Philadelphia.
The respective microRNA seed region influences the production of sensory hair cells in the inner ear, both in the mouse and in humans.
IDEXX Laboratories, Inc., today reported that revenues for the fourth quarter of 2011 increased 8% to $307.2 million, from $283.8 million for the fourth quarter of 2010. Organic revenue growth, as defined below, was 7%. Earnings per diluted share ("EPS") for the quarter ended December 31, 2011 increased 8% to $0.67, compared to $0.62 for the same period in the prior year.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Therachoice Inc. 111 2nd Ave Ne, Suite 900, St Petersburg, FL 33701-3434 Ph: (813) 690-1327 | Therachoice Inc. 111 2nd Ave Ne, Suite 900, St Petersburg, FL 33701-3434 Ph: (813) 690-1327 |
News Archive
Access Pharmaceuticals, Inc., announced today that it has entered into a pre-licensing feasibility agreement with a leading biotechnology company to develop an oral formulation of its currently-marketed, proprietary injectable drugs. Access will utilize its proprietary Cobalamin Oral Drug Delivery Technology to develop oral formulations of the drug for pre-clinical testing.
Dr. Megan Rockafellow-Baldoni, Rutgers School of Public Health alum and Center for Public Health Workforce Development program coordinator, has found a reduction in the risk of cancer due to arsenic exposure in Hopewell Township (Mercer County), New Jersey with use of arsenic treatment systems. Arsenic exists in varying levels in all parts of New Jersey; chronic exposure can increase rates of bladder, lung, liver, kidney, and skin cancers.
Heart function significantly improved in children and young adults with single ventricle congenital heart disease who have had the Fontan operation following treatment with sildenafil, a drug used to treat erectile dysfunction and pulmonary hypertension, say researchers from The Children's Hospital of Philadelphia.
The respective microRNA seed region influences the production of sensory hair cells in the inner ear, both in the mouse and in humans.
IDEXX Laboratories, Inc., today reported that revenues for the fourth quarter of 2011 increased 8% to $307.2 million, from $283.8 million for the fourth quarter of 2010. Organic revenue growth, as defined below, was 7%. Earnings per diluted share ("EPS") for the quarter ended December 31, 2011 increased 8% to $0.67, compared to $0.62 for the same period in the prior year.
› Verified 3 days ago
Anne Marie C Lieser, Speech-Language Pathologist Medicare: May Accept Medicare Assignments Practice Location: 5225 Central Ave, St Petersburg, FL 33710 Phone: 727-954-5635 Fax: 727-914-6904 | |
Miss Lauren Anne Becker, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 111 2nd Ave Ne Ste 900, St Petersburg, FL 33701 Phone: 727-452-1710 | |
Kelli Lauren Wetzel, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1200 7th Ave N, St Petersburg, FL 33705 Phone: 727-825-1189 | |
Julianna Ferguson, MCD, CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4201 31st St S, St Petersburg, FL 33712 Phone: 727-867-1104 | |
Miss Maridyth Marginia Jackson, M.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 11901 10th Way N, #3307, St Petersburg, FL 33716 Phone: 559-288-0713 | |
Cayla Traviesa Dougherty, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 501 6th Ave S, St Petersburg, FL 33701 Phone: 727-898-7451 | |
Alexis Teresa Sanchez, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 867 49th Ave N, St Petersburg, FL 33703 Phone: 954-826-7011 |